
Novo Nordisk's Wegovy injection, a weight loss treatment, could prevent 1.5 million heart attacks and strokes in the U.S. over 10 years. The research, partly funded by Novo Nordisk, indicates significant cardiovascular benefits beyond weight loss. The drug's impact aligns with a previous trial demonstrating a 20% reduction in heart-related risks. Wegovy falls under GLP-1 agonists, sparking interest in obesity drugs, but supply constraints and potential side effects have arisen. The findings may pressure insurers to cover costly obesity medications.
Like
Save
Share